Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Kummar Website

Shivaani Kummar, M.D., F.A.C.P.

Selected Publications

1)  Park SR, Speranza G, Piekarz R, Wright JJ, Kinders RJ, Wang L, Pfister T, Trepel JB, Lee MJ, Alarcon S, Steinberg SM, Collins J, Doroshow JH, Kummar S.
A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas.
Cancer Chemother. Pharmacol. 71: 981-90, 2013.
2)  Kummar S, Allen D, Monks A, Polley EC, Hose CD, Ivy SP, Turkbey IB, Lawrence S, Kinders RJ, Choyke P, Simon R, Steinberg SM, Doroshow JH, Helman L.
Cediranib for metastatic alveolar soft part sarcoma.
J. Clin. Oncol. 31: 2296-302, 2013.
3)  Kummar S, Anderson L, Hill K, Majerova E, Allen D, Horneffer Y, Ivy SP, Rubinstein L, Harris P, Doroshow JH, Collins JM.
First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2"-deoxyribose in patients with advanced malignancies.
Clin. Cancer Res. 19: 1852-7, 2013.
4)  Kummar S, Doroshow JH.
Molecular targets in cancer therapy.
Expert Rev Anticancer Ther. 13: 267-9, 2013.
5)  Kummar S, Gutierrez ME, Anderson LW, Klecker RW, Chen A, Murgo AJ, Doroshow JH, Collins JM.
Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas.
Cancer Chemother. Pharmacol. 2013.
6)  Shibata SI, Chung V, Synold TW, Longmate JA, Suttle AB, Ottesen LH, Lenz HJ, Kummar S, Harvey RD, Hamilton AL, O'Neil BH, Sarantopoulos J, LoRusso P, Rudek MA, Dowlati A, Mulkerin DL, Belani CP, Gandhi L, Lau SC, Ivy SP, Newman EM.
Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
Clin. Cancer Res. 19: 3631-9, 2013.
7)  Park SR, Davis M, Doroshow JH, Kummar S.
Safety and feasibility of targeted agent combinations in solid tumours.
Nat Rev Clin Oncol. 10: 154-68, 2013.
8)  Jeong W, Doroshow JH, Kummar S.
United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies.
Curr Probl Cancer. 37: 110-44, 2013.
9)  Do K, Doroshow JH, Kummar S.
Wee1 kinase as a target for cancer therapy.
Cell Cycle. 12, 2013.
10)  Rajan A, Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, Yancey MA, Ji J, Mannargudi B, Woo S, Spencer S, Figg WD, Giaccone G.
A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.
Clin. Cancer Res. 18: 2344-51, 2012.
Click Here to View Expanded Bibliography.

This page was last updated on 9/18/2013.